The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.

What is known and objective: Genetic polymorphism of interleukin (IL)-1β and IL-1 receptor antagonist (IL-1rα) are associated with efficacy of acid suppression, whereas cytochrome P (CYP) 2C19 polymorphism influences the metabolism of proton pump inhibitor family. Thus, CYP2C19 and IL-1 polymorphism...

Full description

Bibliographic Details
Published in:Journal of Clinical Pharmacy & Therapeutics Vol. 35; no. 6; pp. 713 - 723
Main Authors: Zhang L, Mei Q, Li QS, Hu YM, Xu JM
Format: clinical trial research tables/charts Journal Article
Published: Wiley-Blackwell Dec2010
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104938330&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104938330
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Dec2010
      vid: 35
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        104938330
        104938330
        2010851606
        10.1111/j.1365-2710.2009.01140.x
        NLM21054464
        104938330
      ppf: 713
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
      aug:
        au:
          Zhang L
          Mei Q
          Li QS
          Hu YM
          Xu JM
        affil: Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University
      sug:
        subj:
          Polymorphism, Genetic
          Drug Therapy, Combination
          Helicobacter Infections Drug Therapy
          Proton Pump Inhibitors Metabolism
          Rabeprazole Sodium Therapeutic Use
          Omeprazole Therapeutic Use
          Interleukin 1 Antagonists and Inhibitors
          Hemeproteins
          China
          Human
          Male
          Female
          Adult
          Middle Age
          Clinical Trials
          Random Assignment
          Treatment Outcomes
          Amoxicillin Therapeutic Use
          Clarithromycin Therapeutic Use
          Prospective Studies
          Rabeprazole Sodium Administration and Dosage
          Omeprazole Administration and Dosage
          Peptic Ulcer Drug Therapy
          Academic Medical Centers
          Adolescence
          Aged
          Genotype
          Polymerase Chain Reaction
          Sequence Analysis
          Chi Square Test
          Fisher's Exact Test
          Mann-Whitney U Test
          Data Analysis Software
          Interviews
          Adverse Drug Event
          Confidence Intervals
          Descriptive Statistics
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Adolescent: 13-18 years
          Aged: 65+ years
          Male
          Female
      ab: What is known and objective: Genetic polymorphism of interleukin (IL)-1β and IL-1 receptor antagonist (IL-1rα) are associated with efficacy of acid suppression, whereas cytochrome P (CYP) 2C19 polymorphism influences the metabolism of proton pump inhibitor family. Thus, CYP2C19 and IL-1 polymorphisms may affect the efficacy of H. pylori eradication therapy. We compared the efficacies of omeprazole and rabeprazole on eradication of H. pylori in relation to CYP2C19, IL-1B and IL-1RN genotypes in Chinese people. Methods: Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC). CYP2C19*2 and *3, IL1B-511, IL1B-31, IL1B+ 3954 and intron 2 of the IL-1RN genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism. Results: The intention-to-treat-based cure rate of the OAC regimen was significantly lower than that of the RAC regimen in the CYP2C19 wild-type homozygotes ( P = 0·014). No significant differences in the cure rates were observed among the IL-1RN and the IL-1B genotype groups. What is new and conclusions: The rabeprazole-based triple regimen was better than the omeprazole in Chinese patients with the CYP2C19 extensive metabolizer genotype. The effectiveness of the PPI/AC regimen is unrelated to IL-1B and IL1-RN genetic polymorphism.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N